MCID: MYL009
MIFTS: 72

Myelodysplastic Syndrome malady

Categories: Genetic diseases, Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Myelodysplastic Syndrome

About this section

Aliases & Descriptions for Myelodysplastic Syndrome:

Name: Myelodysplastic Syndrome 49 10 11 12 67 32 65
Myelodysplastic Syndromes 32 45 47 36 24 35
 
Myelodysplastic Syndrome, Somatic 49 11 22
Mds 45 22 67

Characteristics:

HPO:

61
myelodysplastic syndrome:
Inheritance: somatic mutation


Classifications:



External Ids:

OMIM49 614286
Disease Ontology10 DOID:0050908
ICD1027 D46.9, D46
ICD9CM29 238.75
MeSH36 D009190
NCIt42 C3247
MedGen34 C3463824
UMLS65 C0026986, C2713368, C3463824

Summaries for Myelodysplastic Syndrome

About this section
MedlinePlus:35 Your bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. it contains immature cells, called stem cells. the stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting. if you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. many of them die in the bone marrow. this means that you do not have enough healthy cells, which can lead to infection, anemia, or easy bleeding. myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. if you have symptoms, they may include shortness of breath weakness or feeling tired skin that is paler than usual easy bruising or bleeding pinpoint spots under the skin caused by bleeding fever or frequent infections myelodysplastic syndromes are rare. people at higher risk are over 60, have had chemotherapy or radiation therapy, or have been exposed to certain chemicals. treatment options include transfusions, drug therapy, chemotherapy, and blood or bone marrow stem cell transplants. nih: national cancer institute

MalaCards based summary: Myelodysplastic Syndrome, also known as myelodysplastic syndromes, is related to acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor and myelofibrosis, and has symptoms including myelodysplasiaand mass of lymphoreticular structure. An important gene associated with Myelodysplastic Syndrome is GATA2 (GATA Binding Protein 2), and among its related pathways is Transcriptional misregulation in cancer. Affiliated tissues include myeloid, bone and bone marrow, and related mouse phenotypes are embryo and liver/biliary system.

Disease Ontology:10 A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets.

NIH Rare Diseases:45 Myelodysplastic syndromes (mds) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. individuals with mds have abnormally low blood cell levels (low blood counts). signs and symptoms associated with mds include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. in some cases, mds may progress to bone marrow failure or an acute leukemia. the exact cause of mds is unknown. it sometimes runs in families, but no disease-causing gene has been identified. treatment depends on the affected individual's age, general health, and type of mds and may include red cell and/or platelet transfusions and antibiotics. last updated: 3/23/2012

UniProtKB/Swiss-Prot:67 Myelodysplastic syndrome: A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS); chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. MDS is considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML).

OMIM:49 Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematologic stem cell disorders characterized by... (614286) more...

Wikipedia:68 The myelodysplastic syndromes (also known as MDS or myelodysplasia) are hematological (i.e.,... more...

Related Diseases for Myelodysplastic Syndrome

About this section

Diseases related to Myelodysplastic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 318)
idRelated DiseaseScoreTop Affiliating Genes
1acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor34.3FLT3, RUNX1
2myelofibrosis31.7NF1, NRAS, TET2
3hematopoietic stem cell transplantation31.7ETV6, FLT3, GATA2, NPM1, NUP98, RUNX1
4leukemia, acute myelomonocytic, somatic, somatic31.6FLT3, NF1, NRAS, RUNX1, SETBP1, TET2
5acute basophilic leukemia30.9ASXL1, GATA2, SETBP1, TET2
6acute lymphocytic leukemia30.7ETV6, RUNX1
7alpha-thalassemia-myelodysplastic syndrome12.1
8unclassified myelodysplastic syndrome12.1
9therapy related acute myeloid leukemia and myelodysplastic syndrome12.0
10acute myeloid leukemia and myelodysplastic syndromes related to radiation11.9
11acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent11.9
12myelodysplastic syndrome, susceptibility, gata2-related11.8
13macrocytic anemia, refractory, due to 5q deletion, somatic11.8
14miller-dieker lissencephaly syndrome11.4
15myelodysplastic myeloproliferative cancer11.2
16acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2)11.1ETV6, FLT3, RUNX1
17acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)11.1FLT3, NPM1
18acute myeloblastic leukemia without maturation11.1FLT3, GATA2, NPM1
19epidermolysis bullosa simplex with muscular dystrophy11.0
20epidermolysa bullosa simplex with muscular dystrophy11.0
21distal hereditary motor neuropathy, type ii11.0FLT3, NPM1, WT1
22classic hodgkin lymphoma, mixed cellularity type11.0ASXL1, FLT3, RUNX1, TET2
23corticosterone methyloxidase deficiency11.0FLT3, NRAS, RUNX1
24adult central nervous system teratoma11.0FLT3, NPM1, RUNX1
25cell type benign neoplasm11.0ETV6, FLT3, NPM1, RUNX1, TET2
26chronic myocardial ischemia11.0ASXL1, ETV6, FLT3, RUNX1, SETBP1, TET2
276q terminal deletion syndrome11.0SF3B1, TET2
28acute myeloid leukemia, kit-related11.0FLT3, GATA2
29menkes disease11.0
30walker-warburg syndrome11.0
31pericardial tuberculosis11.0ETV6, FLT3, NF1, RUNX1
32nystagmus 3, congenital, autosomal dominant10.9ETV6, FLT3, GATA2, RUNX1, WT1
33herpes simplex encephalitis 110.9FLT3, GATA2, NPM1, RUNX1
34cell type cancer10.9FLT3, NRAS, RUNX1, WT1
35limbal stem cell deficiency10.9ETV6, FLT3, MLF1, NPM1, NRAS, RUNX1
36acute liver failure10.9ETV6, FLT3, RUNX1, WT1
37refractory anemia with excess blasts10.9
38agammaglobulinemia 210.9ETV6, FLT3, GATA2, NUP98, RUNX1, SETBP1
39lateral medullary syndrome10.9ETV6, WT1
40refractory anemia10.9
41adult pulmonary langerhans cell histiocytosis10.9ETV6, FLT3, RUNX1
42leukemia10.9
43subacute monocytic leukemia10.9ETV6, FLT3, GATA2, MLF1, NPM1, NUP98
44muscular dystrophy10.9
45alpha-thalassemia myelodysplasia syndrome, somatic10.8
46familial mosaic monosomy 7 syndrome10.8
47colloid adenoma10.8ETV6, WT1
48chronic polyradiculoneuritis10.8ASXL1, SETBP1
49muscular dystrophy, congenital10.8
50muscular dystrophy-dystroglycanopathy , type a, 110.8

Graphical network of the top 20 diseases related to Myelodysplastic Syndrome:



Diseases related to myelodysplastic syndrome

Symptoms for Myelodysplastic Syndrome

About this section


Clinical features from OMIM:

614286

HPO human phenotypes related to Myelodysplastic Syndrome:

id Description Frequency HPO Source Accession
1 myelodysplasia HP:0002863

UMLS symptoms related to Myelodysplastic Syndrome:


mass of lymphoreticular structure

Drugs & Therapeutics for Myelodysplastic Syndrome

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Busulfex15 41 BUSULFAN Orphan Medical February 1999
FDA Label: Busulfex
Disease/s that Drug Treats:leukemia
Indications and Usage:15 BUSULFEX is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimenprior to allogeneic hematopoietic progenitor cell transplantation forchronic myelogenous leukemia (CML) (1)
DrugBank Targets:13 DNA
Mechanism of Action:15 
Target: DNA
Action: alkylyzer
FDA: Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of afour-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This producesreactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity ofbusulfan.
2
Lynparza15 41 OLAPARIB AstraZeneca December 2014
FDA Label: Lynparza
Disease/s that Drug Treats:previously treated BRCA mutated advanced ovarian cancer
Indications and Usage:15 Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated asmonotherapy in patients with deleterious or suspected deleterious germlineBRCA mutated (as detected by an FDA-approved test) advanced ovariancancer who have been treated with three or more prior lines of chemotherapy.(1.1)The indication is approved under accelerated approval based on objectiveresponse rate and duration of response. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit inconfirmatory trials. (1 1, 14)
DrugBank Targets:13 1. Poly [ADP-ribose] polymerase 1;2. Poly [ADP-ribose] polymerase 2;3. Poly [ADP-ribose] polymerase 3
Mechanism of Action:15 
Target: poly (ADP-ribose) polymerase (PARP)
Action: inhibitor
FDA: Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNArepair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mousexenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increasedcytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor modelswith deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition ofPARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasisand cell death.
3
Revlimid15 41 LENALIDOMIDE Celgene June 2013
FDA Label: Revlimid
Disease/s that Drug Treats:mantle cell lymphoma
Indications and Usage:15 REVLIMID is a thalidomide analogue indicated for the treatment of patientswith: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-riskmyelodysplastic syndromes (MDS) associated with a deletion 5qabnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressedafter two prior therapies, one of which included bortezomib (1.3).Limitations of Use: REVLIMID is not indicated and is not recommended for the treatmentof patients with chronic lymphocytic leukemia (CLL) outside ofcontrolled clinical trials (1.4).
DrugBank Targets:13 1. Protein cereblon;2. Tumor necrosis factor ligand superfamily member 11;3. Cadherin-5;4. Prostaglandin G/H synthase 2
Mechanism of Action:15 
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibitsproliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q)myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor modelsincluding multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increasednumbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, thecombination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.

Drugs for Myelodysplastic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 543)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Cytarabineapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 11035147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosyl Cytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine
Cytarabine (JP15/USP/INN)
 
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
2
FludarabineapprovedPhase 4, Phase 2, Phase 3, Phase 1105921679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-Fluoro-ara AMP
2-Fluoroadenine arabinoside 5'-monophosphate
21679-14-1
2F-Ara-AMP
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
 
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine Phosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
Oforta
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
3
Decitabineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Phase 02082353-33-5451668
Synonyms:
-Deoxycytidine
-azacytidine
2'-Deoxy-5-azacytidine
2353-33-5
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
5-AZAdC
5-Aza-2&prime
5-Aza-2'-deoxycytidine
5-Azadeoxycytidine
5-Deoxy-2&prime
5-aza-2'-deoxycytidine
5-aza-2-deoxycytidine
5-aza-CdR
5-aza-dC
5A2dc
A3656_SIGMA
AC-1135
AC1L9PS9
AzadC
 
Azadc
CHEBI:50131
CHEMBL1201129
CID451668
D03665
DB01262
Dacogen
Dacogen (TN)
Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine
Decitabine
Decitabine (USAN/INN)
Dezocitidine
E-7373
FT-0082622
MLS001332587
MLS001332588
MolMap_000063
NCGC_5ADOC
NSC-127716
NSC127716
S1200_Selleck
SBB066121
SMR000857076
TL8001944
4
TazobactamapprovedPhase 4, Phase 38789786-04-9123630
Synonyms:
(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4
(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
89785-84-2
89786-04-9
AC-7620
AC1L3X07
BIDD:GT0212
C07771
CHEBI:100207
CHEMBL404
 
CID123630
CL-298741
CL298741
D00660
DB01606
MolPort-002-500-123
TAZ
Tazobactam
Tazobactam (JAN/USAN/INN)
YTR-830H
YTR830H
5
IronapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 010217439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Dexiron
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Ed-In-Sol
 
Eisen
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feraheme
Feronate
Ferretts
Ferrlecit
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Infufer
Iron
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Yieronia
fer
ferrous ascorbate
ferrous fumarate
ferrous gluconate
ferrous glycine sulfate
ferrous iron
ferrous succinate
ferrous sulfate
hierro
6
IdarubicinapprovedPhase 4, Phase 3, Phase 2, Phase 119958957-92-942890
Synonyms:
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-|A-l-lyxo-hexopyranoside
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
4-DMD
4-Demethoxydaunomycin
4-Demethoxydaunorubicin
4-Desmethoxydaunorubicin
57852-57-0
57852-57-0 (HYDROCHLORIDE)
58957-92-9
AC1L28SA
AC1Q6JJ4
BRD-K69650333-001-01-1
C26H27NO9
CCRIS 5083
CHEBI:42068
CHEMBL1117
CID42890
D08062
DB01177
DM5
DMDR
EU-0100600
HMS2089D05
I 1656
I06-1097
I1656_SIGMA
IDARUBICIN
IMI 30
 
IMI-30
Idamycin
Idamycin PFS
Idarubicin
Idarubicin (INN)
Idarubicin Aglycone
Idarubicin HCl PFS
Idarubicin Hcl
Idarubicin Hcl Pfs
Idarubicin Hydrochloride
Idarubicin [INN:BAN]
Idarubicina
Idarubicina [INN-Spanish]
Idarubicine
Idarubicine [INN-French]
Idarubicinum
Idarubicinum [INN-Latin]
KBioSS_002388
LS-94015
Lopac0_000600
MLS000759470
NCGC00093976-01
NCGC00093976-02
NCGC00093976-03
NCGC00093976-04
NSC-256439
NSC256439
SMR000466355
UNII-ZRP63D75JW
Zavedos
Zavedos (TN)
idarubicin hydrochloride
7
Epoetin alfaapprovedPhase 4, Phase 3, Phase 2, Phase 1626113427-24-0
Synonyms:
Epogen
 
Erythropoietin precursor
Procrit
8
Busulfanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 150655-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
9
VidarabineapprovedPhase 4, Phase 3, Phase 2, Phase 123824356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
10
ThiotepaapprovedPhase 4, Phase 3, Phase 2, Phase 120552-24-45453
Synonyms:
 
Thioplex
11
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
12
PiperacillinapprovedPhase 4, Phase 38666258-76-243672
Synonyms:
(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
4-ethyl-2,3-dioxopiperazine carbonyl ampicillin
59703-84-3
59703-84-3 (mono-hydrochloride salt)
6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid
61477-96-1
6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid
AC1L2ACR
AC1Q5QXJ
BIDD:GT0167
BPBio1_000848
BRD-K86873305-236-03-0
BSPBio_000770
C14034
C23H27N5O7S
CCRIS 7362
CHEBI:8232
CHEMBL702
CID43672
Cl-227193
D08380
EINECS 262-811-8
HMS2090H19
LS-149794
 
PIPC
PIPERACILLIN SODIUM
Peperacillin
Peracin
Peracin (TN)
Piperacilina
Piperacillin
Piperacillin (INN)
Piperacillin (anhydrous)
Piperacillin Anhydrous
Piperacillin Monosodium Salt
Piperacillin Sodium
Piperacillin anhydrous
Piperacillina
Piperacillinum
Pipercillin
Pipracil
Pipracil, Piper
Pipril
Pipéracilline
Prestwick0_000755
Prestwick1_000755
Prestwick2_000755
Prestwick3_000755
SPBio_002709
T-1220
UNII-9I628532GX
piperacillin
13
Miconazoleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
14
Deferasiroxapproved, investigationalPhase 4, Phase 3, Phase 286201530-41-85493381
Synonyms:
Deferasiroxum
Deferasiroxum [inn-latin]
 
Exjade
ICL 670
ICL 670a
deferasirox
15
Radium Ra 223 dichlorideapproved, investigationalPhase 4, Phase 1, Phase 237444811-40-9
Synonyms:
Radium-223 chloride
 
Radium-223 dichloride
Xofigo
16
SuccinylcholineapprovedPhase 4, Phase 1, Phase 2141306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
17
Posaconazoleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 149171228-49-2147912
Synonyms:
1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one
171228-49-2
177571-33-4
4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one
4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
AC-1350
AC1L3W34
AC1LAHLQ
AKOS005145917
CHEBI:434337
CHEMBL1397
CHEMBL371938
CHEMBL371939
CID10532764
CID11520437
CID11542142
CID147912
CID468595
D02555
DB01263
 
HSDB 7421
LS-186118
LS-186988
LS-187630
MolPort-006-666-426
Noxafil
Noxafil (TN)
Noxafil, Posaconazole
Posaconazole
Posaconazole (USAN/INN)
Posaconazole SP
Posaconazole [USAN:INN:BAN]
Posaconazole in combination with MGCD290
Posanol
S1257_Selleck
SCH-56592
SCH56592
SID144207169
Sch 56592
Spriafil
UNII-6TK1G07BHZ
X2N
posaconazole
18
Azacitidineapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1360320-67-29444
Synonyms:
2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one
320-67-2
4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one
5 AZC
5 Azacytidine
5-AC
5-AZAC
5-AZCR
5-Azacytidine
5-aza-CR
5-azacitidine
5-azacytidine
5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine
5AzaC
A 2385
A1287_SIGMA
A2385_SIGMA
AC1L1T1Y
Antibiotic U 18496
Azacitidina
Azacitidina [INN-Spanish]
Azacitidine
Azacitidine (JAN/USAN/INN)
Azacitidine [USAN:INN]
Azacitidinum
Azacitidinum [INN-Latin]
Azacytidine
BCBcMAP01_000083
BRN 0620461
BSPBio_003157
C11262
CCRIS 60
CHEBI:2038
CHEMBL1489
CID9444
CPD000857239
D001374
D03021
DB00928
DivK1c_000125
EINECS 206-280-2
EU-0100035
FT-0081170
HMS1921J22
HMS2092D08
HMS500G07
HSDB 6879
IDI1_000125
InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
 
Jsp005945
KBio1_000125
KBio2_001742
KBio2_002556
KBio2_004310
KBio2_005124
KBio2_006878
KBio2_007692
KBio3_002657
KBio3_003034
KBioGR_001444
KBioGR_002556
KBioSS_001742
KBioSS_002565
LS-1189
Ladakamycin
Lopac0_000035
MLS001333121
MLS001333122
MLS002153249
MolMap_000062
Mylosar
NCGC00090851-01
NCGC00090851-02
NCGC00090851-03
NCGC00090851-04
NCGC00090851-08
NCGC00178234-01
NCI-C01569
NINDS_000125
NS-17
NSC 102816
NSC-102816
NSC102816
Pharmion Brand of Azacitidine
S1782_Selleck
SAM002264595
SMR000857239
SPBio_000892
SPECTRUM1502111
ST056940
Spectrum2_000786
Spectrum3_001509
Spectrum4_000922
Spectrum5_001166
Spectrum_001262
TL80073599
U 18496
U-18496
UNII-M801H13NRU
Vidaza
Vidaza (TN)
WR-183027
ZINC03861768
cMAP_000082
mylo sar
pyrimidine antimetabolite: inhibits nucleic acid replication
s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI)
wr 183027
19
Micafunginapproved, investigationalPhase 4, Phase 256235114-32-63081921, 477468
Synonyms:
5-[(1S,2S)-2-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-20-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-2,11,12,15-tetrahydroxy-6-[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxo-9-[(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)amino]tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-23-yl}-1,2-dihydroxyethyl]-2-hydroxyphenyl hydrogen sulfate
5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}
AC-6107
AC1L9WY8
AC1MIXSV
CHEBI:600520
CHEMBL1201351
CID11804463
CID3081921
CID477468
 
CID6602291
DB01141
FK-463
FK463
I14-11710
LS-184079
LS-187369
Micafungin
Mycamine
Mycamine(TM)
UNII-R10H71BSWG
20Penicillanic AcidPhase 459
21JM 3100Phase 4, Phase 1, Phase 2125
22Anti-Bacterial AgentsPhase 4, Phase 2, Phase 3, Phase 1, Phase 09140
23
PanobinostatPhase 4, Phase 2, Phase 1132404950-80-76918837
Synonyms:
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
404950-80-7
AC1OCFY8
AKOS005146046
C496932
CHEMBL483254
CID6918837
EC-000.2287
FT-0083488
Faridak
 
LBH 589
LBH-589
LBH-589B
LBH589
MolPort-005-933-338
NVP-LBH-589
NVP-LBH589
Panobinostat
Panobinostat, NVP-LBH589, LBH589
S1030_Selleck
ZINC22010649
nchembio.313-comp11
24Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 19988
25Beta-Lactamase InhibitorsPhase 4, Phase 3245
26Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 110002
27Antiparasitic AgentsPhase 4, Phase 3, Phase 2, Phase 11854
28Histone Deacetylase InhibitorsPhase 4, Phase 2, Phase 1532
29Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Phase 17004
30Antiprotozoal AgentsPhase 4, Phase 3, Phase 2, Phase 11730
31Cytochrome P-450 Enzyme InhibitorsPhase 4, Phase 3, Phase 2, Phase 13036
32Piperacillin, tazobactam drug combinationPhase 4, Phase 368
33EchinocandinsPhase 4, Phase 3, Phase 266
34HormonesPhase 4, Phase 2, Phase 3, Phase 111748
35Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 118510
36Calcineurin InhibitorsPhase 4, Phase 3, Phase 2, Phase 11223
37Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 18496
38CyclosporinsPhase 4, Phase 3, Phase 2, Phase 1873
39Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 14555
40Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018483
41Antilymphocyte SerumPhase 4, Phase 3, Phase 2, Phase 1388
42Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13015
43Antibiotics, AntitubercularPhase 4, Phase 2, Phase 3, Phase 15971
44HematinicsPhase 4, Phase 3, Phase 2, Phase 11121
45AntimetabolitesPhase 4, Phase 2, Phase 3, Phase 1, Phase 09454
46Antimetabolites, AntineoplasticPhase 4, Phase 2, Phase 3, Phase 1, Phase 05770
47Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 010422
48Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 017220
49Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 1, Phase 03572
50Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 13582

Interventional clinical trials:

(show top 50)    (show all 1668)
idNameStatusNCT IDPhase
1Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)CompletedNCT01201811Phase 4
2Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic SyndromeCompletedNCT00488436Phase 4
3Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron OverloadCompletedNCT00564941Phase 4
4A Study for Dacogen Treatment in Patients With Myelodysplastic SyndromeCompletedNCT01041846Phase 4
5An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic SyndromeCompletedNCT01400633Phase 4
6SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaCompletedNCT00487448Phase 4
7Survey on QUality of Life In myeloDisplasia (SQUID)CompletedNCT00967564Phase 4
8Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron OverloadCompletedNCT00481143Phase 4
9Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over LoadCompletedNCT00452660Phase 4
10Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron OverloadCompletedNCT00673608Phase 4
11Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003398Phase 4
12This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.CompletedNCT01250951Phase 4
13Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)CompletedNCT00361140Phase 4
14LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk MDSCompletedNCT01034657Phase 4
15Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of PlerixaforCompletedNCT01362985Phase 4
16Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic PatientsCompletedNCT00195533Phase 4
17A Phase Ⅳ Study of Decitabine in Myelodysplastic SyndromeRecruitingNCT02013102Phase 4
18An Open-Label Study of Recormon (Epoetin Beta) Treatment in Anemic Patients With Myelodysplastic SyndromeRecruitingNCT02145026Phase 4
19Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic SyndromesRecruitingNCT01674985Phase 4
20A Rollover Study to Provide Continued Treatment With EltrombopagRecruitingNCT01957176Phase 4
21Radium-223 Dichloride Long-term Follow-up ProgramRecruitingNCT02312960Phase 4
22Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT01200355Phase 4
23Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell TransplantationActive, not recruitingNCT01806116Phase 4
24A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.Not yet recruitingNCT02663752Phase 4
25Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)Not yet recruitingNCT01339988Phase 4
26Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability StudyTerminatedNCT01326845Phase 4
27To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.TerminatedNCT01011283Phase 4
28Transfusion Effects in Myelodysplastic Patients: Limiting ExposureWithdrawnNCT00202371Phase 4
29The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment ProtocolApproved for marketingNCT00438789Phase 3
30S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid LeukemiaCompletedNCT00005866Phase 3
31Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic SyndromeCompletedNCT00004208Phase 3
32Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT00454480Phase 2, Phase 3
33Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic SyndromeCompletedNCT00003593Phase 3
34A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional CareCompletedNCT00071799Phase 3
35Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic SyndromesCompletedNCT00003138Phase 3
36An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic SyndromeCompletedNCT01751867Phase 3
37An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic SyndromesCompletedNCT01381809Phase 3
38Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous LeukemiaCompletedNCT00322101Phase 3
39Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00002798Phase 3
40Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic SyndromeCompletedNCT01409070Phase 3
41An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT01186939Phase 3
42Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00002517Phase 3
43IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeCompletedNCT00469144Phase 3
44Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)CompletedNCT00422890Phase 3
45Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00005823Phase 3
46Decitabine Versus Supportive Care in Adults With Advanced-stage MDSCompletedNCT00043381Phase 3
47A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDSCompletedNCT00656448Phase 3
48Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic LymphomaCompletedNCT00003187Phase 2, Phase 3
49Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] AbnormalityCompletedNCT00179621Phase 3
50A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic SyndromesCompletedNCT00050843Phase 3

Search NIH Clinical Center for Myelodysplastic Syndrome

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myelodysplastic Syndrome cell therapies at LifeMap Discovery.

Genetic Tests for Myelodysplastic Syndrome

About this section

Genetic tests related to Myelodysplastic Syndrome:

id Genetic test Affiliating Genes
1 Myelodysplastic Syndrome, Somatic22 SF3B1, TET2, ASXL1

Anatomical Context for Myelodysplastic Syndrome

About this section

MalaCards organs/tissues related to Myelodysplastic Syndrome:

33
Myeloid, Bone, Bone marrow, T cells, Testes, Lung, Kidney

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myelodysplastic Syndrome:
id TissueAnatomical CompartmentCell Relevance
1 PlacentaChorionic VillusChorionic Mesenchymal Stromal Cells Potential therapeutic candidate
2 Umbilical CordWharton's JellyMesenchymal Stem Cells Potential therapeutic candidate
3 BloodCord BloodMesenchymal Stem Cells Potential therapeutic candidate

Animal Models for Myelodysplastic Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Myelodysplastic Syndrome:

38 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538010.6ETV6, GATA2, NF1, NPM1, NRAS, NUP98
2MP:000537010.6ASXL1, GATA2, NF1, NPM1, NRAS, PRDM16
3MP:000287310.6ETV6, GATA2, NF1, NRAS, PRDM16, RUNX1
4MP:000200610.5ASXL1, ETV6, FLT3, NF1, NPM1, NRAS
5MP:000537910.5ASXL1, ETV6, FLT3, GATA2, NF1, NRAS
6MP:000538410.3ASXL1, ETV6, FLT3, GATA2, NF1, NPM1
7MP:000538510.3ETV6, GATA2, NF1, NPM1, NRAS, PRDM16
8MP:000537810.2ASXL1, ETV6, FLT3, GATA2, NF1, NPM1
9MP:001076810.2ASXL1, ETV6, FLT3, GATA2, NF1, NPM1
10MP:000538710.1ASXL1, ETV6, FLT3, NF1, NPM1, NRAS
11MP:000539710.1ASXL1, ETV6, FLT3, GATA2, NF1, NPM1

Publications for Myelodysplastic Syndrome

About this section

Articles related to Myelodysplastic Syndrome:

(show top 50)    (show all 2071)
idTitleAuthorsYear
1
Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome. (26497198)
2015
2
Ollier's Disease with Myelodysplastic Syndrome. (26454395)
2015
3
Biological activities of RUNX1 mutants predict secondary acute leukemia transformation from chronic myelomonocytic leukemia and myelodysplastic syndromes. (25840971)
2015
4
Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. (24434998)
2014
5
The GNAS1 gene in myelodysplastic syndromes (MDS). (24795070)
2014
6
Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients. (24127668)
2013
7
NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. (23708912)
2013
8
Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. (23259989)
2013
9
Fatal Nocardia farcinica Bacteremia Diagnosed by Matrix-Assisted Laser Desorption-Ionization Time of Flight Mass Spectrometry in a Patient with Myelodysplastic Syndrome Treated with Corticosteroids. (23690786)
2013
10
Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome. (23826588)
2013
11
Large-vessel thrombosis in intestinal BehAset's disease complicated with myelodysplastic syndrome and trisomy 8. (22416191)
2012
12
Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. (21233837)
2011
13
Myelodysplastic syndromes. (22118747)
2011
14
Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature. (20371446)
2010
15
Single nucleotide polymorphisms in the human TNF gene are associated with anaemia and neutropenia in a cohort of patients with de novo myelodysplastic syndrome. (20618340)
2010
16
Mutation analysis of the HAX1 gene in childhood myelodysplastic syndrome. (19298594)
2009
17
Update on genetic and molecular markers associated with myelodysplastic syndromes. (19263296)
2009
18
Expression of cyclin A1 mRNA in patients with myelodysplastic syndrome and its clinical significance]. (19379570)
2009
19
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. (17940203)
2008
20
Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. (18195096)
2008
21
Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes. (18464119)
2008
22
GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes. (17570514)
2007
23
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. (17550846)
2007
24
A case of myelodysplastic syndrome complicated with organizing pneumonia]. (17233390)
2006
25
WT1 gene expression lowered by IL-12 In vitro in peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes. (16800930)
2006
26
Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density. (15888251)
2005
27
Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes. (15863212)
2005
28
The geldanamycin derivative 17-AAG decreases VEGF secretion and leukemia growth support by trisomy 8 myelodysplastic syndrome bone marrow stromal cells. (15804996)
2005
29
Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors. (15590394)
2004
30
Survivin expression in acute leukemias and myelodysplastic syndromes. (15512811)
2004
31
Cord blood transplantation supported with ex vivo expanded fraction for a patient with myelodysplastic syndrome and metastatic breast cancer]. (15510834)
2004
32
Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. (12681357)
2003
33
Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. (12937849)
2003
34
Secondary pulmonary alveolar proteinosis associated with myelodysplastic syndrome. (12636240)
2003
35
Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome. (12469185)
2003
36
Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. (11830484)
2002
37
Cellular abundance of es nucleoside transporters and differential drug toxicity in myelodysplastic syndrome (MDS) bone marrow cell subpopulations. (11794010)
2001
38
An elderly patient with myelodysplastic syndrome successfully treated with combination of granulocyte-colony stimulating factor and continuous-drip infusion of low-dose cytarabine and etoposide]. (10774251)
2000
39
Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. (10997969)
2000
40
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. (10211754)
1999
41
Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase. (7532031)
1994
42
Response of hematopoietic precursor cells to hematopoietic growth factors in the myelodysplastic syndromes. (2099409)
1990
43
44
45
46
47
48
49
50

Variations for Myelodysplastic Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Myelodysplastic Syndrome:

67
id Symbol AA change Variation ID SNP ID
1GATA2p.Thr354MetVAR_066406
2SETBP1p.Asp868AsnVAR_063807
3SETBP1p.Gly870SerVAR_063809
4SETBP1p.Ser869AsnVAR_069852
5SETBP1p.Thr873ArgVAR_069857

Clinvar genetic disease variations for Myelodysplastic Syndrome:

5
id Gene Variation Type Significance SNP ID Assembly Location
1GATA2NM_001145661.1(GATA2): c.1061C> T (p.Thr354Met)single nucleotide variantPathogenic, risk factorrs387906631GRCh37Chr 3, 128200744: 128200744
2GATA2GATA2, 3-BP DEL, 1063ACAdeletionrisk factor
3MT-TL1m.3242G> Asingle nucleotide variantPathogenicrs193303018GRCh37Chr MT, 3242: 3242

Expression for genes affiliated with Myelodysplastic Syndrome

About this section
Search GEO for disease gene expression data for Myelodysplastic Syndrome.

Pathways for genes affiliated with Myelodysplastic Syndrome

About this section

Pathways related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
110.2ETV6, FLT3, MLF1, RUNX1, WT1

GO Terms for genes affiliated with Myelodysplastic Syndrome

About this section

Biological processes related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1myeloid progenitor cell differentiationGO:000231810.9FLT3, MLF1, TET2
2tissue developmentGO:000988810.9GATA2, WT1
3adrenal gland developmentGO:003032510.4NF1, WT1
4regulation of transcription, DNA-templatedGO:000635510.2ASXL1, GATA2, PRDM16, RUNX1, WT1
5germ cell developmentGO:000728110.1PAFAH1B1, WT1

Molecular functions related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein homodimerization activityGO:004280310.3ACSL6, FLT3, NPM1, RUNX1

Sources for Myelodysplastic Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet